Bioxytran, Inc.
BIXT
$0.109
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 165.60K | 454.00K | 295.20K | 609.40K | 752.20K |
| Depreciation & Amortization | 1.90K | 2.90K | 1.50K | 1.50K | 2.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 517.00K | 491.20K | 347.70K | 610.90K | 781.30K |
| Operating Income | -517.00K | -491.20K | -347.70K | -610.90K | -781.30K |
| Income Before Tax | -1.35M | -516.90K | -392.40K | -661.70K | -573.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.35M | -516.90K | -392.40K | -661.70K | -573.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 13.30K | -- | -- | 13.30K |
| Net Income | -1.35M | -503.60K | -392.40K | -661.70K | -560.50K |
| EBIT | -517.00K | -491.20K | -347.70K | -610.90K | -781.30K |
| EBITDA | -515.10K | -488.30K | -346.20K | -609.40K | -779.20K |
| EPS Basic | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 88.84M | 92.93M | 126.39M | 176.61M | 163.45M |
| Average Diluted Shares Outstanding | 88.84M | 92.93M | 126.39M | 176.61M | 163.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |